BioSante Pharmaceuticals, Inc. to Host Conference Call to Announce LibiGel(R) Special Protocol Assessment (SPA)

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will host a conference call tomorrow, Tuesday, January 29, 2008 at 11:00 a.m. ET to announce and discuss the LibiGel (testosterone gel) SPA received from the U.S. Food and Drug Administration (FDA) for the development of LibiGel in the treatment of female sexual dysfunction.
MORE ON THIS TOPIC